Status:
Concluded without agreement
Manufacturer:
AVIR Pharma Inc.
Indication:
Eosinophilic Esophagitis (Maintenance)
Last updated July 20, 2022
Status:
Concluded without agreement
Manufacturer:
AVIR Pharma Inc.
Indication:
Eosinophilic Esophagitis (Induction)
Last updated July 20, 2022
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older
Last updated July 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Metastatic colorectal cancer (mCRC) in patients with a BRAF V600E mutation, as detected by a validated test, after prior therapy (in combination with cetuximab)
Last updated July 6, 2022
Braftovi/Mektovi (encorfenib/binimetinib)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test, (encorafenib and binimetinib in combination)
Last updated July 6, 2022
Status:
Concluded without agreement
Manufacturer:
Sanofi Genzyme Canada
Indication:
Asthma
Last updated June 28, 2022
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated June 28, 2022
Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated June 15, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Last updated June 7, 2022
Status:
Concluded without agreement
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated June 1, 2022